

Health Disparities and Impacting Factors

in Patients With Chronic
Kidney Disease (CKD)
Associated With
Type 2 Diabetes (T2D)

© 2024 Bayer. BAYER and the Bayer Cross are registered trademarks of Bayer.
All other trademarks are the property of their respective owners.
All rights reserved. MAC-UN-CAR-US-0190-1 1/25





Table of contents

Overview of CKD in T2D population

3

Health disparities

4

SDoH factors impacting the CKD with T2D population

5


Takeaways and resources

7

Chronic kidney disease remains underdiagnosed and undertested



~36.4 million people in the United States have T2D, and at least 40% of those patients also have CKD^{1,2}



~90% of patients with diabetes and CKD are unaware of their kidney disease³



ADA, KDIGO, ESC, and AACE guidelines **recommend uACR and eGFR testing at least annually** for all patients with T2D⁴⁻⁷



A 2021 published study reported **80.0%** of at-risk patients with CKD **did not receive guidelines-based testing**.

Only 21.0% of all at-risk patients had at least 1 uACR test, compared with 89.6% of patients who had an eGFR test⁸

AACE, American Association of Clinical Endocrinology; ADA, American Diabetes Association; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESC, European Society of Cardiology; KDIGO, Kidney Disease Improving Global Outcomes; T2D, type 2 diabetes; uACR, urine albumin-creatinine ratio.

References: 1. American Diabetes Association. Accessed July 12, 2024. [https://diabetes.org/about-diabetes](https://diabetes.org/about-diabetes/statistics/about-diabetes) 2. Bailey RA et al. *BMC Res Notes*. 2014;7:415.

3. United States Renal Data System. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Accessed July 15, 2024. <https://usrds-adr.niddk.nih.gov/2020/chronic-kidney-disease/1-ckd-in-the-general-population> 4. American Diabetes Association Professional Practice Committee. *Diabetes Care*. 2024;47(suppl 1):S219-S230.

5. de Boer IH et al. *Kidney Int*. 2022;102(5):974-989. 6. Marx N et al. *Eur Heart J*. 2023;44(39):4043-4140. 7. Blonda L et al. *Endocr Pract*. 2022;28(10):923-1049. 8. Alfego D et al. *Diabetes Care*. 2021;44(9):2025-2032.



Though gaps in care exist for all patients with CKD associated with T2D, minority groups are disproportionately impacted



Increased Comorbidities

Black or African Americans have much **higher rates of high blood pressure, diabetes, and additional comorbidities** that increase the risk for kidney disease¹



Higher Prevalence

According to the Centers for Disease Control and Prevention, **CKD is more common in non-Hispanic Blacks (16.3%) and Hispanics (13.6%)** than in non-Hispanic Whites (12.7%) or non-Hispanic Asians (12.9%)²



Lower Screening Rates

Lower KED fulfillment of recommended testing was found among Black or African American patients (30%-36%) and groups that have been economically marginalized (26%-35%)³



Worse Outcomes

Compared with White Americans:

- Hispanics or Latinos are **1.3 times more likely to have kidney failure**¹
- Black or African Americans are **almost 4 times more likely** to have kidney failure¹
- The mortality rate over 4 years from kidney disease among Black individuals is **more than twice that among White individuals** (28.2% vs 12.4%)⁴

CKD, chronic kidney disease; KED, Kidney Health Evaluation for Patients With Diabetes; T2D, type 2 diabetes.

References: 1. National Kidney Foundation. Accessed July 12, 2024. <https://www.kidney.org/advocacy/legislative-priorities/health-disparities> 2. Centers for Disease Control and Prevention. March 4, 2021. Accessed October 17, 2023. <https://nccd.cdc.gov/CKD/Documents/Chronic-Kidney-Disease-in-the-US-2021-h.pdf> 3. Ferrè S et al. *Mayo Clin Proc Innov Qual Outcomes*. 2023;7(5):382-391. 4. Benjamins MR et al. *J Gen Intern Med*. 2022;37(6):1351-1358.



Social determinants of health (SDoH) can make it harder for patients to be healthy and get the medical care and support they need¹

What are SDoH?

- SDoH are nonmedical factors that influence health outcomes, such as conditions in which people are born, grow, work, live, and age. SDoH can be grouped into 5 domains²:



Economic Stability*



Education Access and Quality†



Healthcare and Quality‡



Neighborhood and Built Environment§



Social and Community Context||

- These factors include economic policies, development agendas, social norms, social policies, racism, climate change, and political structures²

The risk of developing CKD may be higher in some people due to SDoH caused by race-based economic and political decisions that have systemically been set in place¹

*Economic stability is the connection between people's financial resources and their health. This includes income/employment, socioeconomic status/poverty level, food security, and housing stability.³

[†]Education access and quality refers to a person's ability to participate in education programs.⁴

[‡]Healthcare and quality refers to access to healthcare and primary care, health insurance, and health literacy.⁵

[§]Neighborhood and built environment refers to quality of housing, access to transportation, and neighborhood crime and violence.⁶

^{||}Social and community context refers to the cohesion and participation within a community, conditions in a workplace, and incarceration.⁷

CKD, chronic kidney disease; T2D, type 2 diabetes.

References: 1. National Kidney Foundation. Updated January 2, 2023. Accessed July 12, 2024. <https://www.kidney.org/atoz/content/social-determinants-health-and-chronic-kidney-disease#sdoh-and-ckd> 2. Centers for Disease Control and Prevention. May 15, 2024. Accessed July 12, 2024. <https://www.cdc.gov/public-health-gateway/php/about/social-determinants-of-health.html#:~:text=These%20forces%20and%20systems%20encompass,in%20its%20key%20health%20indicators> 3. Centers for Disease Control and Prevention. Accessed August 28, 2024. <https://www.cdc.gov/preyourhealth/discussinguides/economicstability.htm> 4. Centers for Disease Control and Prevention. Accessed August 28, 2024. <https://www.cdc.gov/preyourhealth/discussinguides/education.htm> 5. Centers for Disease Control and Prevention. Accessed August 28, 2024. <https://www.cdc.gov/preyourhealth/discussinguides/healthcare.htm#:~:text=Health%20care%20access%20and%20quality%20includes%20key%20issues%2C%20such%20as,such%20as%20mental%20health%20services> 6. Centers for Disease Control and Prevention. Accessed August 28, 2024. <https://www.cdc.gov/preyourhealth/discussinguides/neighborhood.htm#:~:text=and%20Built%20Environment,Neighborhood%20and%20Built%20Environment,their%20health%20and%20well%20being> 7. Centers for Disease Control and Prevention. Accessed August 28, 2024. <https://www.cdc.gov/preyourhealth/discussinguides/community.htm#:~:text=Social%2026%20Community%20Context,Social%2026%20Community%20Context,the%20conditions%20of%20daily%20life>



Poor socioeconomic factors increase an individual's likelihood of developing CKD and indicate potentially poorer prognosis¹



Food Insecurity

Nearly **1 in 3 adults** with CKD experienced food insecurity (2017-2020)²



Socioeconomic

Data show that **as a county's poverty level increases, so does the prevalence of diagnosed CKD among Medicare beneficiaries**^{3,4}



Housing Insecurity

Unstable housing or homelessness was associated with an **increased risk** of end-stage renal disease or death in patients with kidney disease⁵

CKD, chronic kidney disease; SDoH, social determinants of health; T2D, type 2 diabetes.

References: 1. Shlipak MG et al. *Kidney Int.* 2021;99(1):34-47. 2. Centers for Disease Control and Prevention. Accessed July 12, 2024. <https://nccd.cdc.gov/CKD/detail.aspx?Qnum=Q712&Strat=CKD#refreshPosition> 3. Centers for Disease Control and Prevention. Accessed October 11, 2024. https://www.cdc.gov/pcd/issues/2024/23_0286.htm#T1_down 4. Centers for Disease Control and Prevention. Accessed July 15, 2024. <https://nccd.cdc.gov/CKD/detail.aspx?Qnum=Q783#refreshPosition> 5. Hall YN et al. *Clin J Am Soc Nephrol.* 2012;7(7):1094-1102.



Health disparities and inequities increase an individual's chances of developing CKD and impact minorities at greater rates



Black or African Americans are **more likely to have comorbidities that increase the risk of kidney disease, are almost 4 times more likely to have kidney failure, and have more than twice the kidney disease-related mortality rate** as compared to White individuals^{1,2}



Although evidence-based kidney health testing is recommended by the AACE, ADA, ESC, and KDIGO³⁻⁶, lower rates of KED fulfillment of recommended testing were found in Black or African American patients⁷



SDoH, which include healthcare access and quality, economic policies, social policies, and racism, **disproportionately impact patients of different racial backgrounds**^{8,9}

AACE, American Association of Clinical Endocrinology; ADA, American Diabetes Association; CKD, chronic kidney disease; ESC, European Society of Cardiology; KDIGO, Kidney Disease Improving Global Outcomes; KED, Kidney Health Evaluation for Patients With Diabetes; SDoH, social determinants of health.

References: 1. National Kidney Foundation. Accessed July 12, 2024. <https://www.kidney.org/advocacy/legislative-priorities/health-disparities> 2. Benjamins MR et al. *J Gen Intern Med*. 2022;37(6):1351-1358. 3. American Diabetes Association Professional Practice Committee. *Diabetes Care*. 2024;47(suppl 1):S219-S230. 4. Marx N et al. *Eur Heart J*. 2023;44(39):4043-4140. 5. de Boer IH et al. *Kidney Int*. 2022;102(5):974-989. 6. Blonde L et al. *Endocr Pract*. 2022;28(10):923-1049. 7. Ferré S et al. *Mayo Clin Proc Innov Qual Outcomes*. 2023;7(5):382-391. 8. National Kidney Foundation. Updated January 2, 2023. Accessed July 12, 2024. <https://www.kidney.org/atoz/content/social-determinants-health-and-chronic-kidney-disease#sdoh-and-ckd> 9. Centers for Disease Control and Prevention. May 15, 2024. Accessed July 12, 2024. <https://www.cdc.gov/public-health-gateway/php/about/social-determinants-of-health.html>



Reducing inequities involves both broad and targeted initiatives, with a goal to improve testing, diagnosis, and treatment

What you can do:

 Drive eGFR and uACR testing for all patients with T2D at least annually

 Ensure patients with lab-indicated CKD receive a diagnosis

 Support treatment with guidelines-directed medical therapies

 Analyze data to detect testing and treatment inequities between patient populations (race, geography, etc). Target under-served populations with HCP and patient education

How we can help:

HCP webinars:

- Highlight the importance of testing, diagnosing, and treating patients, as well as the impact of CKD associated with T2D on CV health

Unbranded educational resources:

For health plans, PBMs, and health system HCPs:

CKD-T2D-for-Pop-Health.com



For patients:

CKDandT2d.com



Partnerships with health plans and health systems, aimed to:

- Improve uACR and eGFR testing rates for patients with T2D
- Educate on the impact of albuminuria, including poor CV outcomes
- Inform HCPs on treatment guidelines for CKD associated with T2D



Clinical guidelines support

National Kidney Foundation (NKF) KDOQI clinical practice guidelines:
kidney.org/professionals/kdoqi



American Society of Nephrology (ASN) guidelines:
epc.asn-online.org/resource_lib/diabetic-kidney-disease



Kidney Disease Improving Global Outcomes (KDIGO) guidelines:
kdigo.org/guidelines/diabetes-ckd

